Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05126290 · ClinicalTrials.gov registry record
CTNNA1 Familial Expansion Study
A clinical trial of Breast Cancer and Gastric Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05126290 is a study of Breast Cancer and Gastric Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05126290, a study of Breast Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.
Conditions Studied
Interventions
- OTHER Collection of personal and family history from CAFÉ Study participants
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2028-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05126290
The ClinicalTrials.gov registry entry for NCT05126290 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Collection of personal and family history from CAFÉ Study participants is the first listed.
NCT05126290 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05126290 about?
NCT05126290 is a clinical study titled "CTNNA1 Familial Expansion Study". The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.
What is the current status of trial NCT05126290?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-03-16. Estimated completion is 2028-01-01.
What conditions does trial NCT05126290 study?
This clinical trial studies the following conditions: Breast Cancer, Gastric Cancer, Cancer Gene Mutation.
What interventions are being tested in trial NCT05126290?
The interventions under investigation include: Collection of personal and family history from CAFÉ Study participants (OTHER).
Who is sponsoring clinical trial NCT05126290?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05126290 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.